Lymphoma is one of the most common malignant neoplasms of lymphohematopoietic system, and non-Hodgkin lymphoma (NHL) is the major type (approximately 80%) of lymphoma. NHL is a group of highly heterogeneous diseases in terms of clinical manifestations, molecular pathogenesis mechanisms, and responses to treatment. NHL can originate from lymph node or extranodual organs. Imaging examinations play important roles in guiding diagnosis, differential diagnosis, and disease monitoring of lymphoma after treatment. Contrast-enhanced ultrasound (CEU) not only shows small structure of organs, but also displays their blood perfusion state. Signal enhancement can be realized in CEU examination via using contrast agents. By combining quantitative (e.g., enhancement patterns) and qualitative (e.g., intensity-time curves) analysis, CEU can distinguish malignant diseases from benign lesions, and make differential diagnosis of different malignant tumors. Therefore, CEU has some advantages in monitoring therapeutic effect of lymphoma, and in diagnosis, differential diagnosis of primary extranodual lymphoma.